

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA **复星医药**

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

POLL RESULTS OF THE RESOLUTIONS PROPOSED AT THE 2024 FIRST EXTRAORDINARY GENERAL MEETING HELD ON FRIDAY, 27 SEPTEMBER 2024 AND ELECTION OF NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) is pleased to announce the poll results of the 2024 first extraordinary general meeting (the “**EGM**”) held at Sky Fortune Boutique Hotel Shanghai, No. 358 Hong Xu Road, Shanghai, the PRC on Friday, 27 September 2024 at 1:30 p.m.

References are made to the notice of the EGM and the circular (the “**Circular**”) of the Company, both dated 19 August 2024. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

As at the record date of the EGM, (i) the total number of the issued shares of the Company (the “**Shares**”) was 2,672,398,711 Shares, comprising 2,120,458,211 A Shares and 551,940,500 H Shares; and (ii) holders of 2,662,074,311 Shares (comprising 2,115,207,311 A Shares and 546,867,000 H Shares) (or by authorized proxies) were entitled to attend and vote on the resolutions proposed at the EGM. There were no Shares entitling the Shareholders to attend and vote only against the resolution at the EGM.

To the best knowledge, information and belief of the Directors, having made all reasonable enquiries, no Shareholder has any material interest in the resolutions proposed at the EGM and was required to abstain from voting at the EGM. No Shareholder has stated in the Circular his/her/its intention to vote against any resolution at the EGM.

ATTENDANCE AT THE EGM

Set out below are the details of the Shareholders and authorised proxies present at the EGM:

Number of Shareholders and authorised proxies	3,171
<i>Including:</i> Number of A Shareholders	3,169
Number of H Shareholders	2
Total number of Shares carrying voting rights (shares)	1,089,723,630
<i>Including:</i> Total number of Shares carrying voting rights held by A Shareholders (shares)	956,121,020
Total number of Shares carrying voting rights held by H Shareholders (shares)	133,602,610
Percentage of the total number of Shares carrying voting rights (%)	40.9351
<i>Including:</i> Number of A Shares as a percentage of the total number of Shares carrying voting rights (%)	35.9164
Number of H Shares as a percentage of the total number of Shares carrying voting rights (%)	5.0187

The EGM was convened in compliance with the requirements of the Company Law and the Articles of Association, and was chaired by Mr. Wu Yifang, the chairman of the Company. The Company has eleven (11) directors in office (such expression does not include Mr. Chen Yuqing, whose appointment as a non-executive Director of the ninth session of the Board was approved by the Shareholders at the EGM). Six (6) Directors of the Company, including four (3) executive Directors, namely Mr. Wu Yifang, Mr. Wang Kexin and Mr. Wen Deyong; one (1) non-executive Directors, namely Mr. Pan Donghui; and Two (2) independent non-executive Directors, namely Ms. Li Ling and Mr. Wang Quandi attended the EGM.

In compliance with the requirements of the Hong Kong Listing Rules and Article 115 of the Articles of Association in effect at the time of the EGM, BDO Limited, Grandall Law Firm (Shanghai)* (國浩律師(上海)事務所), the Company's PRC legal advisers, the Shareholder's representatives and member(s) of the supervisory committee of the Company acted as the scrutineers for the vote-counting at the EGM.

POLL RESULTS OF THE RESOLUTIONS PROPOSED AT THE EGM

All resolutions at the EGM were voted on by poll. The poll results in respect of the resolutions proposed at the EGM were as follows:

ORDINARY RESOLUTION		Number of valid votes		
		For	Against	Abstain
1.	To elect Mr. Chen Yuqing as a non-executive Director.	1,081,473,384 (99.2429%)	7,436,210 (0.6824%)	814,036 (0.0747%)
As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.				

SPECIAL RESOLUTION		Number of valid votes		
		For	Against	Abstain
2.	To consider and approve the amendments to the Articles of Association and its Appendices.	1,086,396,599 (99.6947%)	2,457,395 (0.2255%)	869,636 (0.0798%)
As more than two-thirds of the votes were cast in favour of this resolution, the resolution was duly passed as a special resolution.				

CERTIFICATION

As certified by and stated in the legal opinion issued by Grandall Law Firm (Shanghai)* (國浩律師(上海)事務所), the Company's PRC legal advisers, the convening and holding of the EGM are in compliance with requirements of the relevant laws, administrative regulations, the Rules of General Meetings of Listed Companies and the Articles of Association, the qualifications of the attendees of the EGM and the convener are legally valid, and the voting procedures and voting results of the EGM are legally valid.

ELECTION OF NON-EXECUTIVE DIRECTOR

At the EGM, Mr. Chen Yuqing (陳玉卿) (“**Mr. Chen**”) was duly elected by the Shareholders as a non-executive Director of the ninth session of the Board, and the appointment is effective from 27 September 2024 until the term of the current session of the Board expires.

The biographical details of Mr. Chen are set out as follow:

Mr. Chen Yuqing, aged 48. Mr. Chen had been a teacher at the School of Materials of Shanghai University, the human resources manager of each of Yanfeng Visteon Automotive Trim Systems Co., Ltd.* (延鋒偉世通汽車飾件系統有限公司) (now renamed as Yanfeng Automotive Trim Systems Co., Ltd.* (延鋒汽車飾件系統有限公司)), Yanfeng Visteon (Beijing) Automotive Trim Systems Co., Ltd.* (延鋒偉世通(北京)汽車飾件系統有限公司) and Shanghai Yanfeng Johnson Controls Seating Co., Ltd.* (上海延鋒江森座椅有限公司), the development manager of the human resources department of Shanghai Alison (Group) Co., Ltd.* (上海埃力生(集團)有限公司), the Central China human resources

manager of Schindler China Elevator Co. Ltd.* (迅達(中國)電梯有限公司), the senior human resources integration manager of Global Mart Limited* (購寶商業集團), and the chief human resources director of Kubao Information Technology (Shanghai) Co., Ltd.* (酷寶信息技術(上海)有限公司) from July 1997 to October 2009. Mr. Chen served in various positions including the deputy supervisor of human resources department, deputy general manager of human resources department, general manager of human resources department, the assistant to the president and general manager of the human resources department of the Company from January 2010 to April 2015; the vice president of the Company from April 2015 to June 2016; senior vice president of the Company from June 2016 to October 2020; the co-president of the Company from October 2020 to June 2022; a co-chief executive officer of the Company from June 2022 to June 2023; chairman of Shanghai Fosun Health Technology (Group) Co., Ltd.* (上海復星健康科技(集團)有限公司) (“**Fosun Health**”), a subsidiary of the Company, from August 2020 to May 2021 and from October 2022 to present, and holds directorships in certain subsidiaries of Fosun Health; and vice president of the Fosun International Limited (stock code: 00656), a company listed on the Hong Kong Stock Exchange, from July 2023 to present. Mr. Chen obtained a bachelor degree in engineering from Shanghai University.

Mr. Chen has confirmed that, save as disclosed above, as at the date of this announcement, he did not have any relationship with any Directors, supervisors, senior management or substantial or controlling shareholders of the Company, and did not hold any other positions in the Company or any subsidiaries of the Company nor any directorships in listed public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years.

The Company will enter into the relevant director service contract with Mr. Chen for a term commencing from the date of Shareholders’ approval at the EGM until the expiration of the term of the ninth session of the Board. Mr. Chen will not receive any remuneration from the Company as a non-executive Director, and the relevant directors’ service contract will not provide for a specific remuneration amount.

Mr. Chen has confirmed that, as at the date of this announcement, Mr. Chen has personal interests in 134,000 A Shares and 20,000 H Shares of the Company, representing approximately 0.0063% of the Company’s total number of issued A Shares and approximately 0.0036% of the total number of issued H Shares of the Company, which in aggregate represented approximately 0.0058% of the total number of Shares of the Company. Save as disclosed above, Mr. Chen is not interested or deemed to be interested in any shares or underlying shares of the Company within the meaning of Part XV of the SFO.

Mr. Chen has confirmed that, as at the date of this announcement, he has not been punished by the CSRC or any other relevant department(s) or reprimanded by the stock exchange(s). Save as disclosed above, there is no other information that needs to be disclosed pursuant to Rule 13.51(2) of the Hong Kong Listing Rules nor any other matters relating to the appointment of Mr. Chen as a non-executive Director of the ninth session of the Board that needs to be brought to the attention of the Shareholders.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Wu Yifang
Chairman

Shanghai, the PRC
27 September 2024

As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui and Mr. Wen Deyong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Xu Xiaoliang, Mr. Pan Donghui and Mr. Chen Yuqing; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

* *For identification purposes only*